Antisense modulation of C-reactive protein expression

Details Antisense modulation of C-reactive protein expression Antisense modulation of C-reactive protein expression

2005-08-25

2009-02-17

McGarry, Sean R (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C514S04400A, C536S023100, C536S024100, C435S006120

Reexamination Certificate

active

07491815

ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.

REFERENCES:
patent: 5582979 (1996-12-01), Weber
patent: 5783179 (1998-07-01), Nestor, Jr. et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6764826 (2004-07-01), Yeh et al.
patent: 6770461 (2004-08-01), Carulli et al.
patent: 6964950 (2005-11-01), Crooke et al.
patent: 7326693 (2008-02-01), Crooke et al.
patent: 2002/0142283 (2002-10-01), Yeh et al.
patent: 2003/0207834 (2003-11-01), Dale et al.
patent: 2004/0241651 (2004-12-01), Olek et al.
patent: 2004/0241844 (2004-12-01), Crooke et al.
patent: 2005/0014257 (2005-01-01), Crooke et al.
patent: WO 96/06624 (1996-03-01), None
patent: WO 99/00418 (1999-01-01), None
patent: WO 00/11207 (2000-03-01), None
Skerra, A. Nucleic Acids Research vol. 20(14):3551-3554, 1992.
Agrawal, SudhirTIBTECH, Oct. 1996 14(376-387).
Arici etal., “End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link?”,Kidney Intl.2001 59:407-414.
Bárány P., “Inflammation, serum C-reactiveprotein, and erythropoietin resistance”,Nephrol. Dial Transplant2001 16:224-227.
Bennett et al., “Antisense oligonucleotides as a tool for gene functionalization and target validation”,Biochem. Biophys. Acta1999 1489(1):19-30.
Branch, AndreaTIBS 23, Feb. 1998 45-50.
Gabay et al., “Acute-Phase Proteins and Other Systemic Responses to Inflammation”,New England J. of Medicine1999 448-454.
Highton et al., “The Presence and Possible Significance of C-Reactive Protein in Rheumatoid Inflammation”,J. Rheumatology1985 871-875.
Hulthe et al., “Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: The Atherosclerosis and Insulin Resistance (AIR) study”,Clinical Science2001 100:371-378.
Jen, et al.,Stem Cells, 2000 18:307-319.
LaGrand et al., “C-Reactive Protein as a Cardiovascular Risk Factor More Than an Epiphenomenon?”,CRP and Cardiovascular Disease1999 96:102.
Lei et al., “Genomic DNA Sequence for Human C-reactive Protein”,J. Biol. Chem.1985 260(24):13377-13383.
Morrow et al., “C-Reactive Protein, Inflammation, and Coronary Risk”,Med. Clinics of North America2000 84(1):149-161.
Ridker et al., “Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events”,N. Engl. J. Med.2001 344(6):1959-1965.
Ridker et al., “Rapid Reduction in C-Reactive Protein with Cerivastatin Among 785 Patients with Primary Hypercholesterolemia”,Circulation2001 1191-1193.
Ruuskanen et al., “C-reactive protein in respiratory virus infections”,J. Pediatrics1985 97-100.
Szalai et al., “C-Reactive Protein Structural Biology, Gene Expression, and Host Defense Function”,Immunologic Research1997 16/2:127-136.
Weintraub, Harold M.Scientific American,40-46.
Westhuyzen et al., “Review: Biology and Relevance of C-Reactive Protein in Cardiovascular and Renal Disease”,Annals of Clinical&Laboratory Science2000 30(2):133-143.
Woo, et al., “Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component”,J. Biol Chem.1985 260(24):13384-13388.
Yudkin et al., “Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?”,Atherosclerosis2000 148:209-214.
Random Primer 24, New England Biolabs, 1998/99 New England Biolabs catalog, cover page, p. 121 and p. 284.
Non-final Office Action mailed Nov. 22, 2006, U.S. Appl. No. 10/483,424, now U.S. Patent No. 7,326,693.
Notice of Allowance mailed Mar. 13, 2008 for U.S. Appl. No. 10/858,500.
Notice of Allowance for U.S. Appl. No. 09/912,724, now U.S. Patent No. 6,964,950.
Final Office Action mailed Dec. 9, 2004 for U.S. Appl. No. 09/912,724, now U.S. Patent No. 6,964,950.
Final Office Action mailed Jun. 9, 2004 for U.S. Appl. No. 09/912,724, now U.S. Patent No. 6,964,950.
Non-final Office Action mailed Dec. 15, 2003 for U.S. Appl. No. 09/912,724, now U.S. Patent No. 6,964,950.
Final Office Action mailed Mar. 13, 2003 for U.S. Appl. No. 09/912,724, now U.S. Patent No. 6,964,950.
Non-final Office Action mailed Sep. 20, 2002 for U.S. Appl. No. 09/912,724, now U.S. Patent No. 6,964,950.
Supplemental European Search Report issued Mar. 17, 2005 for European Patent Application No. 02753388.4-2403, which corresponds to U.S. Appl. No. 11/211,803.
Restriction Requirement for U.S. Appl. No. 10/483,424 mailed Jul. 24, 2006.
Restriction Requirement for U.S. Appl. No. 10/858,500 mailed Jan. 11, 2007.

Affiliated with

Also associated with

Rating

Antisense modulation of C-reactive protein expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense modulation of C-reactive protein expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of C-reactive protein expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4119480